NeuroSense Therapeutics Ltd.·4

Apr 1, 4:26 PM ET

Eisenberg Or 4

4 · NeuroSense Therapeutics Ltd. · Filed Apr 1, 2026

Research Summary

AI-generated summary of this filing

Updated

NeuroSense CFO Or Eisenberg Receives 200,000-Share Award

What Happened

  • Or Eisenberg (CFO) received a grant of 200,000 restricted common shares (transaction code A) on 2026-03-26. The reported acquisition price is $0.00 (i.e., a compensatory award), so the filing shows $0 cash paid.

Key Details

  • Transaction date: 2026-03-26; reported on Form 4 filed 2026-04-01.
  • Shares granted: 200,000; reported acquisition price: $0.00; total cash paid: $0.
  • Shares owned after transaction: not disclosed in this filing.
  • Footnote: The restricted shares vest in equal quarterly installments over a two-year period beginning March 26, 2026, subject to continued service.
  • No 10b5-1 plan, tax-withholding sale, or late-filing flag was indicated in the filing.

Context

  • This is a compensatory equity award (not an open-market purchase or sale), common for executives as part of pay or retention programs. Vesting over two years means the shares are earned over time and depend on continued service rather than an immediate market position change. Such grants are informative about company compensation but do not by themselves indicate immediate buying or selling by the insider.

Insider Transaction Report

Form 4
Period: 2026-03-26
Eisenberg Or
Chief Financial Officer
Transactions
  • Award

    Ordinary Shares

    [F1]
    2026-03-26+200,0001,254,050 total
Footnotes (1)
  • [F1]The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
Signature
/s/ Or Eisenberg|2026-04-01

Documents

1 file
  • 4
    ownership.xmlPrimary

    OWNERSHIP DOCUMENT